| Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
|---|---|---|---|---|---|
Gross Sales | 263.07 | 286.96 | 272.21 | 244.13 | 215.82 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 263.07 | 286.96 | 272.21 | 244.13 | 215.82 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 13.96 | 22.01 | 39.82 | 76.15 | 78.17 |
Total Income | 277.03 | 308.97 | 312.03 | 320.28 | 293.99 |
Total Expenditure | 270.06 | 293.15 | 286.08 | 258.44 | 299.47 |
PBIDT | 6.97 | 15.82 | 25.95 | 61.84 | -5.48 |
Interest | 1.85 | 1.67 | 1.91 | 2.01 | 2.43 |
PBDT | 5.12 | 14.15 | 24.04 | 59.83 | -7.91 |
Depreciation | 17.41 | 17.92 | 18.79 | 19.18 | 19.94 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 0 | 0.69 | 0 | 2.56 | 0 |
Deferred Tax | -1.12 | -0.27 | 2.56 | 31.4 | 12.59 |
Reported Profit After Tax | -11.17 | -4.19 | 2.69 | 6.69 | -40.44 |
Minority Interest After NP | 0 | -0.33 | 0 | 0 | 0 |
Net Profit after Minority Interest | -11.17 | -3.86 | 2.69 | 6.69 | -40.44 |
Extra-ordinary Items | 5.51 | 5.52 | 27.95 | 47.15 | 42.92 |
Adjusted Profit After Extra-ordinary item | -16.68 | -9.38 | -25.26 | -40.46 | -83.36 |
EPS (Unit Curr.) | -1.8 | 0 | 0.44 | 1.09 | -6.6 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 6.13 | 6.13 | 6.13 | 6.13 | 6.13 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 2.64 | 5.51 | 9.53 | 25.33 | -2.53 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | -4.24 | -1.46 | 0.98 | 2.74 | -18.73 |
Such a contract symbolizes Panacea Biotec's continued commitment toward global health by contributing its share of the fight against polio, a deadly disease prevalent in many pockets of the world.
Panacea Biotec's stock has seen a 37% gain over the past six months. Panacea Biotec's stock has gained a total of 76% in the last one year.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
